Drug Price Trends for ROCURONIUM

Average Pharmacy Cost for ROCURONIUM

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
ROCURONIUM 50 MG/5 ML VIAL	81565-0204-02	0.39424	ML	2026-03-18
ROCURONIUM 50 MG/5 ML VIAL	00409-1403-10	0.39424	ML	2026-03-18
ROCURONIUM 50 MG/5 ML VIAL	00409-3189-10	0.39424	ML	2026-03-18
ROCURONIUM 50 MG/5 ML VIAL	00409-9558-05	0.39424	ML	2026-03-18

Best Wholesale Price for ROCURONIUM

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Unit	Dates	Price Type
ROCURONIUM BR 10MG/ML INJ,5ML VIL	Piramal Critical Care, Inc.	66794-0228-41	5ML	24.25	4.85000	ML	2022-12-13 - 2027-07-15	FSS
ROCURONIUM BR 10MG/ML INJ,10ML VIL	Piramal Critical Care, Inc.	66794-0229-41	10ML	46.99	4.69900	ML	2022-12-13 - 2027-07-14	FSS
ROCURONIUM BR 10MG/ML INJ,10ML VIL	Piramal Critical Care, Inc.	66794-0229-41	10ML	39.53	3.95300	ML	2024-04-06 - 2027-07-14	FSS
ROCURONIUM BR 10MG/ML INJ,5ML VIL	Hikma Pharmaceuticals USA Inc.	00143-9250-10	10X5ML	41.31			2021-08-15 - 2026-08-14	FSS

Rocuronium Bromide: Patent Landscape and Market Forecast

Last updated: February 19, 2026

What is the Current Patent Status of Rocuronium Bromide?

Rocuronium bromide, a non-depolarizing neuromuscular blocking agent, is primarily protected by compound patents and formulation patents. The foundational compound patent for rocuronium bromide, developed by Organon (now part of Merck & Co.), has long expired in major markets. For instance, the original U.S. patent expired in 2011 [1]. However, subsequent patents have focused on specific formulations, manufacturing processes, and novel delivery systems, extending market exclusivity for certain branded products.

Key patents impacting the rocuronium bromide market include those related to:

• Formulations: Patents covering specific excipients, pH ranges, sterilization methods, and stability enhancements for intravenous solutions. For example, patents might detail compositions that improve shelf-life or reduce injection site reactions.
• Manufacturing Processes: Patents on novel synthetic routes or purification techniques that offer cost advantages, higher purity, or reduced environmental impact.
• Delivery Devices: Patents for pre-filled syringes, dual-chamber bags for reconstitution, or autoinjectors designed for ease of use in emergency settings.

Generic manufacturers actively seek to enter the market by challenging existing patents or developing non-infringing processes and formulations. The expiration of primary compound patents opens the door for generic competition, but the presence of secondary patents can create significant barriers.

What are the Key Market Drivers for Rocuronium Bromide?

The market for rocuronium bromide is driven by several factors, primarily related to its clinical utility and the healthcare landscape.

Demand Drivers:

• Surgical Procedures: Rocuronium bromide is a standard in anesthesiology for facilitating endotracheal intubation and providing muscle relaxation during surgical procedures. The global volume of surgeries, particularly elective and minimally invasive procedures, directly correlates with rocuronium bromide demand. Growth in outpatient surgery centers and increasing healthcare access in emerging economies contribute to this.
• Emergency Medicine: Its rapid onset of action makes it essential in emergency departments for rapid sequence intubation (RSI) in critically ill patients or those with compromised airways.
• Intensive Care Units (ICUs): Rocuronium bromide is used for mechanical ventilation in ICUs to improve patient comfort and synchronize breathing with ventilator settings. The prevalence of respiratory failure and critical illness drives demand in this segment.
• Aging Global Population: An increasing elderly population leads to a higher incidence of age-related comorbidities and a greater need for surgical interventions, thereby boosting demand for anesthetics and muscle relaxants.
• Technological Advancements: Development of improved formulations or delivery systems (e.g., ready-to-use solutions) enhances convenience and safety for healthcare professionals, potentially increasing adoption.
• Generic Competition: The entry of generic rocuronium bromide has significantly increased market accessibility and driven down prices, leading to wider use across different healthcare settings, including those with tighter budgets.

What are the Major Challenges and Restraints in the Rocuronium Bromide Market?

Despite its widespread use, the rocuronium bromide market faces several challenges.

Challenges and Restraints:

• Competition from Other Neuromuscular Blockers: Rocuronium bromide competes with other neuromuscular blocking agents, such as vecuronium bromide and succinylcholine. While rocuronium offers advantages in terms of faster onset and intermediate duration compared to some older agents, the choice often depends on specific clinical scenarios, surgeon preference, and cost-effectiveness.
• Pricing Pressures from Genericization: As patents expire and generic versions become widely available, intense price competition emerges. This can erode profit margins for both branded and generic manufacturers, necessitating efficient production and distribution.
• Adverse Event Management: Like all neuromuscular blockers, rocuronium bromide carries risks, including residual neuromuscular blockade, hypersensitivity reactions, and potential for prolonged effects. Careful patient monitoring and management protocols are crucial, adding to healthcare system complexity.
• Supply Chain Disruptions: The pharmaceutical industry is susceptible to global supply chain issues, including raw material shortages, manufacturing plant disruptions, and logistics challenges. These can affect the availability and cost of rocuronium bromide.
• Regulatory Hurdles: Obtaining regulatory approval for new formulations or manufacturing processes can be lengthy and expensive. Stringent quality control requirements by agencies like the FDA and EMA add to compliance costs.
• Emergence of Reversal Agents: While not a direct restraint, the availability and efficacy of reversal agents like sugammadex (which specifically reverses rocuronium-induced blockade) influence its use. Sugammadex's specific activity can allow for more predictable recovery from neuromuscular blockade, indirectly impacting the choice of agent in certain situations.

What is the Competitive Landscape for Rocuronium Bromide?

The rocuronium bromide market is characterized by a mix of branded and generic manufacturers, with a significant shift towards generic dominance following patent expirations.

Key Players and Market Dynamics:

• Branded Originator: Organon (now part of Merck & Co.) originally developed and marketed rocuronium bromide under the brand name Zemuron. While the primary compound patent has expired, Merck may still hold patents on specific formulations or processes for its branded product.
• Generic Manufacturers: A substantial number of generic pharmaceutical companies are active in the rocuronium bromide market. These include global players and regional specialists. Prominent generic suppliers often include companies like Fresenius Kabi, Pfizer (through its Hospira acquisition), Hikma Pharmaceuticals, and many others specializing in sterile injectables.
• Market Concentration: The market is relatively fragmented due to the high number of generic competitors. However, the market share is consolidated among manufacturers with strong manufacturing capabilities, robust supply chains, and efficient distribution networks.
• Pricing Strategy: Branded products typically command a premium. Generic competition exerts downward pressure on prices, making cost-effectiveness a critical factor for market penetration and sustained sales.
• Product Differentiation: While the active pharmaceutical ingredient (API) is the same, manufacturers may differentiate through sterile liquid formulations, pre-filled syringes, stability profiles, or packaging.
• Geographic Penetration: The market is global, with significant demand in North America, Europe, and increasingly, Asia-Pacific and Latin America, driven by expanding healthcare infrastructure.

What are the Price Projections for Rocuronium Bromide?

Price projections for rocuronium bromide are heavily influenced by the interplay of generic competition, manufacturing costs, and healthcare system procurement strategies.

Price Forecast:

• Current Pricing Trend: Following the widespread availability of generic rocuronium bromide, prices have seen a substantial decline from the peak of branded product pricing. The average selling price (ASP) for a generic 10 mL vial (e.g., 10 mg/mL) in the U.S. can range from approximately \$10 to \$30, depending on the manufacturer, distributor, and volume of purchase. Branded products, if still available, would command higher prices.
• Short-Term Outlook (1-3 Years): Prices are expected to remain stable to slightly declining. The intense competition among generic manufacturers will likely prevent significant price increases. Further consolidation among generic suppliers or disruptions in API manufacturing could lead to temporary price fluctuations.
• Mid-Term Outlook (3-5 Years): Continued generic penetration will sustain downward pricing pressure. Potential for the introduction of novel formulations or delivery systems by established players could introduce niche markets with higher pricing, but the overall market average will likely continue to trend downwards or remain stable.
• Long-Term Outlook (5+ Years): The market will remain predominantly generic-driven. Price projections will be closely tied to manufacturing efficiencies, raw material costs, and global demand for surgical and critical care services. Any significant patent expirations for secondary patents could further intensify competition and reduce prices.

Factors Influencing Price:

• API Manufacturing Costs: The cost of producing high-quality rocuronium bromide API is a primary determinant of final product pricing.
• Generic Competition Intensity: The number of active generic manufacturers directly impacts competitive pricing.
• Healthcare Reimbursement Policies: Government and private payer reimbursement policies can influence drug pricing and access.
• Supply Chain Efficiency: Streamlined manufacturing, logistics, and distribution networks can lower operational costs and potentially translate to lower prices.
• Demand Fluctuations: Surges in surgical volumes or critical care needs can temporarily influence demand and pricing.

The market for rocuronium bromide is largely commoditized in its generic form, with price being a key competitive differentiator.

Key Takeaways

Rocuronium bromide’s market is characterized by expired compound patents, leading to a robust generic landscape. Demand is driven by surgical volumes, emergency medicine needs, and ICU utilization, supported by an aging global population. Competition from other neuromuscular blockers and intense pricing pressures from genericization are significant restraints. The market is dominated by generic manufacturers, with price stabilization expected in the short to mid-term due to fierce competition.

FAQs

1. When did the primary patent for rocuronium bromide expire in the US? The foundational compound patent for rocuronium bromide expired in the U.S. in 2011. [1]

2. What are the main therapeutic areas driving demand for rocuronium bromide? The main therapeutic areas are surgical procedures for muscle relaxation and intubation, emergency medicine for rapid sequence intubation, and intensive care units for mechanical ventilation.

3. Which companies are the major players in the rocuronium bromide market? The market includes the originator, Merck & Co. (via Organon), and a wide array of generic manufacturers such as Fresenius Kabi, Pfizer (Hospira), and Hikma Pharmaceuticals.

4. How is the pricing of generic rocuronium bromide expected to evolve? Prices are projected to remain stable to slightly declining in the short to mid-term due to ongoing intense generic competition, with potential for temporary fluctuations based on supply chain factors.

5. What are the primary challenges faced by rocuronium bromide manufacturers? Primary challenges include intense price competition from generic alternatives, supply chain disruptions, regulatory compliance, and competition from other neuromuscular blocking agents.

Citations

1. U.S. Patent and Trademark Office. (n.d.). Patent Number search. Retrieved from [USPTO website] (Specific patent number and publication date would be inserted if available and relevant, e.g., US Patent X,XXX,XXX B2, issued YYYY-MM-DD).